Relationships between body composition parameters and fluorouracil pharmacokinetics
Open Access
- 1 August 2002
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 54 (2) , 131-139
- https://doi.org/10.1046/j.1365-2125.2002.01598.x
Abstract
Aims To verify whether fluorouracil (FU) clearance (CL) and volume of distribution (Vss) are better correlated with specific body compartments, such as body cell mass (BCM), total body water (TBW) or fat free mass (FFM), rather than with body surface area (BSA) or total body weight (BW). Methods Thirty‐four patients (13 females and 21 males) affected by colorectal cancer and receiving FU as adjuvant therapy entered the study. CL and Vss were determined after a 2 min i.v. injection of FU (425 mg m−2) and leucovorin (20 mg m−2). Body composition, in terms of BCM, TBW and FFM, was evaluated non‐invasively by bioelectrical impedance analysis (BIA). Results Significant but poor correlations were found between CL or Vss and most anthropometric parameters, including BIA‐derived measures (r2 range=0.10–0.21). However, when multiple regression analysis was performed with sex, TBW and FFM as independent variables, the correlations improved greatly. The best correlation was obtained between CL and sex (r2=0.44) and between Vss and sex (r2=0.36). FFM‐normalized CL was significantly higher in women than in men (0.030±0.008 vs 0.022±0.005 l min−1 kg−1; 95% CI of difference 0.012, 0.003; P=0.003), suggesting that FU metabolism is more rapid in females. Surprisingly, Vss was highly correlated with CL (r2=0.67; CL=0.52+Vss×0.040). This finding may either be explained by extensive drug metabolism in extra‐hepatic organs or by variable inactivation on first‐pass through the lung. Both these hypotheses need experimental validation. Conclusions The pharmacokinetics of FU are better predicted by FFM and TBW than by standard anthropometric parameters and predictions are sex‐dependent. The use of BIA may lead to improved dosing with FU.Keywords
This publication has 28 references indexed in Scilit:
- Can Pharmacokinetic Monitoring Improve Clinical Use of Fluorouracil?Clinical Pharmacokinetics, 1999
- Different Intravenous Administration Techniques for 5-Fluorouracil Pharmacokinetics and Pharmacodynamic EffectsActa Oncologica, 1996
- Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy*Clinical Pharmacology & Therapeutics, 1995
- Dihydropyrimidine dehydrogenase activity in cancer patientsEuropean Journal Of Cancer, 1993
- Transport of 5-fluorouracil and uracil into human erythrocytesBiochemical Pharmacology, 1993
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patientsEuropean Journal of Clinical Pharmacology, 1987
- Geometric method for measuring body surface area: A height-weight formula validated in infants, children, and adultsThe Journal of Pediatrics, 1978
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974